173 related articles for article (PubMed ID: 23934106)
1. Recombinant TIMP-1-GPI inhibits growth of fibrosarcoma and enhances tumor sensitivity to doxorubicin.
Bao Q; Niess H; Djafarzadeh R; Zhao Y; Schwarz B; Angele MK; Jauch KW; Nelson PJ; Bruns CJ
Target Oncol; 2014 Sep; 9(3):251-61. PubMed ID: 23934106
[TBL] [Abstract][Full Text] [Related]
2. Exogenously added GPI-anchored tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) displays enhanced and novel biological activities.
Djafarzadeh R; Mojaat A; Vicente AB; von Lüttichau I; Nelson PJ
Biol Chem; 2004 Jul; 385(7):655-63. PubMed ID: 15318815
[TBL] [Abstract][Full Text] [Related]
3. Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction.
Stucke-Ring J; Ronnacker J; Brand C; Höltke C; Schliemann C; Kessler T; Schmidt LH; Harrach S; Mantke V; Hintelmann H; Hartmann W; Wardelmann E; Lenz G; Wünsch B; Müller-Tidow C; Mesters RM; Schwöppe C; Berdel WE
Oncotarget; 2016 Dec; 7(50):82458-82472. PubMed ID: 27738341
[TBL] [Abstract][Full Text] [Related]
4. TRAIL and taurolidine enhance the anticancer activity of doxorubicin, trabectedin and mafosfamide in HT1080 human fibrosarcoma cells.
Harati K; Chromik AM; Bulut D; Goertz O; Hahn S; Hirsch T; Klein-Hitpass L; Lehnhardt M; Uhl W; Daigeler A
Anticancer Res; 2012 Jul; 32(7):2967-84. PubMed ID: 22753761
[TBL] [Abstract][Full Text] [Related]
5. TIMP-1-GPI in combination with hyperthermic treatment of melanoma increases sensitivity to FAS-mediated apoptosis.
Djafarzadeh R; Milani V; Rieth N; von Luettichau I; Skrablin PS; Hofstetter M; Noessner E; Nelson PJ
Cancer Immunol Immunother; 2009 Mar; 58(3):361-71. PubMed ID: 18618109
[TBL] [Abstract][Full Text] [Related]
6. Recombinant GPI-anchored TIMP-1 stimulates growth and migration of peritoneal mesothelial cells.
Djafarzadeh R; Sauter M; Notohamiprodjo S; Noessner E; Goyal P; Siess W; Wörnle M; Ribeiro A; Himmelein S; Sitter T; Nelson PJ
PLoS One; 2012; 7(4):e33963. PubMed ID: 22558080
[TBL] [Abstract][Full Text] [Related]
7. Treatment of dermal fibroblasts with GPI-anchored human TIMP-1 protein moderates processes linked to scar formation.
Djafarzadeh R; Notohamiprodjo S; Rieth N; Hofstetter M; Noessner E; Nelson PJ
J Invest Dermatol; 2013 Mar; 133(3):803-811. PubMed ID: 23096710
[TBL] [Abstract][Full Text] [Related]
8. GPI-anchored TIMP-1 treatment renders renal cell carcinoma sensitive to FAS-meditated killing.
Djafarzadeh R; Noessner E; Engelmann H; Schendel DJ; Notohamiprodjo M; von Luettichau I; Nelson PJ
Oncogene; 2006 Mar; 25(10):1496-508. PubMed ID: 16261161
[TBL] [Abstract][Full Text] [Related]
9. Peritumoral administration of GPI-anchored TIMP-1 inhibits colon carcinoma growth in Rag-2 gamma chain-deficient mice.
Raggi MC; Djafarzadeh R; Muenchmeier N; Hofstetter M; Jahn B; Rieth N; Nelson PJ
Biol Chem; 2009 Sep; 390(9):893-7. PubMed ID: 19558322
[TBL] [Abstract][Full Text] [Related]
10. The histone deacetylase inhibitor vorinostat selectively sensitizes fibrosarcoma cells to chemotherapy.
Sampson ER; Amin V; Schwarz EM; O'Keefe RJ; Rosier RN
J Orthop Res; 2011 Apr; 29(4):623-32. PubMed ID: 20957741
[TBL] [Abstract][Full Text] [Related]
11. Transforming growth factor-beta1 induces tissue inhibitor of metalloproteinase-1 expression via activation of extracellular signal-regulated kinase and Sp1 in human fibrosarcoma cells.
Kwak HJ; Park MJ; Cho H; Park CM; Moon SI; Lee HC; Park IC; Kim MS; Rhee CH; Hong SI
Mol Cancer Res; 2006 Mar; 4(3):209-20. PubMed ID: 16547158
[TBL] [Abstract][Full Text] [Related]
12. Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents.
Koto K; Murata H; Kimura S; Horie N; Matsui T; Nishigaki Y; Ryu K; Sakabe T; Itoi M; Ashihara E; Maekawa T; Fushiki S; Kubo T
Oncol Rep; 2010 Jul; 24(1):233-9. PubMed ID: 20514467
[TBL] [Abstract][Full Text] [Related]
13. CD133+ subpopulation of the HT1080 human fibrosarcoma cell line exhibits cancer stem-like characteristics.
Feng BH; Liu AG; Gu WG; Deng L; Cheng XG; Tong TJ; Zhang HZ
Oncol Rep; 2013 Aug; 30(2):815-23. PubMed ID: 23708735
[TBL] [Abstract][Full Text] [Related]
14. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors.
Vanhoefer U; Cao S; Minderman H; Toth K; Skenderis BS; Slovak ML; Rustum YM
Clin Cancer Res; 1996 Dec; 2(12):1961-8. PubMed ID: 9816155
[TBL] [Abstract][Full Text] [Related]
15. Targeting a Designer TIMP-1 to the Cell Surface for Effective MT1-MMP Inhibition: A Potential Role for the Prion Protein in Renal Carcinoma Therapy.
Jiang B; Liu J; Lee MH
Molecules; 2019 Jan; 24(2):. PubMed ID: 30641935
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicity.
Albright CF; Graciani N; Han W; Yue E; Stein R; Lai Z; Diamond M; Dowling R; Grimminger L; Zhang SY; Behrens D; Musselman A; Bruckner R; Zhang M; Jiang X; Hu D; Higley A; Dimeo S; Rafalski M; Mandlekar S; Car B; Yeleswaram S; Stern A; Copeland RA; Combs A; Seitz SP; Trainor GL; Taub R; Huang P; Oliff A
Mol Cancer Ther; 2005 May; 4(5):751-60. PubMed ID: 15897239
[TBL] [Abstract][Full Text] [Related]
17. Intensive fibrosarcoma-binding capability of the reconstituted analog and its antitumor activity.
Xu J; Du Y; Liu WJ; Li L; Li Y; Wang XF; Yi HF; Shan CK; Xia GM; Liu XJ; Zhen YS
Drug Deliv; 2018 Nov; 25(1):102-111. PubMed ID: 29250984
[TBL] [Abstract][Full Text] [Related]
18. Translocating a High-Affinity Designer TIMP-1 to the Cell Membrane for Total Renal Carcinoma Inhibition: Putting the Prion Protein to Good Use.
Jiang B; Xu Y; Zhang Y; Lee MH
Mol Cell Biol; 2019 Sep; 39(18):. PubMed ID: 31208977
[No Abstract] [Full Text] [Related]
19. Ensnaring membrane type 1-matrix metalloproteinase (MT1-MMP) with tissue inhibitor of metalloproteinase (TIMP)-2 using the haemopexin domain of the protease as a carrier: a targeted approach in cancer inhibition.
Jiang B; Zhang Y; Liu J; Tsigkou A; Rapti M; Lee MH
Oncotarget; 2017 Apr; 8(14):22685-22699. PubMed ID: 28186971
[TBL] [Abstract][Full Text] [Related]
20. Pro‑apoptotic effects of pycnogenol on HT1080 human fibrosarcoma cells.
Harati K; Slodnik P; Chromik AM; Behr B; Goertz O; Hirsch T; Kapalschinski N; Klein-Hitpass L; Kolbenschlag J; Uhl W; Lehnhardt M; Daigeler A
Int J Oncol; 2015 Apr; 46(4):1629-36. PubMed ID: 25625225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
